Not provided
Not provided
Not provided
Not provided
COVID pandemic
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a randomized, double-blind, crossover study in healthy adult subjects. Each subject will receive a single dose of bisoprolol 5 mg p.o. and nebivolol 5 mg p.o. with 1 week washout period. All subjects will undergo a physical examination, 12-lead electrocardiography and a comprehensive echocardiographic study before the administration of the study drug and 5 hours thereafter.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bisoprolol first, Nebivolol Second | Experimental | In this arm, patient will first receive bisoprolol, and after 1 week washout period, nebivolol |
|
| Nebivolol first, Bisoprolol second | Experimental | In this arm, patient will first receive nebivolol, and after 1 week washout period, bisoprolol |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bisoprolol versus Nebivolol | Drug | All subjects will receive both drugs, but at different time periods determined by randomization, with 1 week washout period |
|
| Measure | Description | Time Frame |
|---|---|---|
| Relative change (%) of cardiac output (CO) | CO (l/min), will be assessed by calculating stroke volume using pulsed-wave doppler (velocity time integral) | Pre- and 5 hours post study drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Absolute and relative changes of left ventricular ejection fraction (%) | Ejection fraction will be measured using modified Simpson rule | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of global longitudinal strain (%) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Hospital Centre Zemun | Belgrade | 11080 | Serbia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Global longitudinal strain will be assessed using speckle tracking echocardiography
| Pre- and 5 hours post study drug administration |
| Absolute and relative changes of myocardial work (%) | Myocardial work will be assessed by using a dedicated commercially available software (GE, Norway) | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of atrial function (ml) | Atrial function will be assessed by measuring phasic volume changes during diastole | Pre- and 5 hours post study drug administration |
| Absolute change of myocardial dispersion (ms) | Myocardial dispersion will be assessed by using speckle tracking echocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of TAPSE (tricuspid annular plane systolic excursion, mm) | TAPSE will be assessed by M-mode echocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of blood pressure (mmHg) | Brachial blood pressure will be measured by sphygmomanometer | Pre- and 5 hours post study drug administration |
| Absolute and relative changes in atrial strain (%) | Atrial strain will be assessed using speckle tracking echocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of electrical dispersion (ms) | Electrical dispersion will be assessed by using 12-lead electrocardiogram | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of right ventricular fractional area change (%) | The parameter will be assessed by two-dimensional echocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of heart rate (bpm) | Heart rate will be measured by 12-lead electrocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of left ventricular twist (%) | Twist will be assessed by speckle tracking echocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of QTc interval (ms) | QTc interval will be measured by using 12-lead electrocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of mitral E/A ratio (%) | E/A ratio will be assessed by pulsed-wave Doppler | Pre- and 5 hours post study drug administration |
| Absolute and relative change of mitral E/e prime ratio (%) | E/e prime ratio will be assessed by pulsed-wave and tissue Doppler echocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative change of mitral E-wave deceleration time (ms) | E-wave deceleration time will be measured by pulsed-wave Doppler echocardiography | Pre- and 5 hours post study drug administration |
| Absolute and relative changes of right ventricular global longitudinal strain (%) | Global strain will be assessed by using speckle tracking echocardiography | Pre- and 5 hours post study drug administration |